Therapeutic Potential of T-Cell Receptor Targeting Shared Neoantigens in Solid Cancers

Strategic Insights -

Researchers at Chongqing Medical University in China have made significant advancements in the field of cancer immunotherapy. According to a recent study published in the Journal for ImmunoTherapy of Cancer, investigators have discovered that shared neoantigens, including KRAS, TP53, and PIK3CA mutations, have substantial immunogenicity and offer promising therapeutic potential against solid tumors.

These public neoantigens have been identified across various tumor types and have shown remarkable efficacy in clinical trials, resulting in tumor regression and prolonged relapse-free survival. The study's findings have shed light on the HLA binding properties of T-cell epitopes derived from these shared neoantigens, which hold immense potential for developing T-cell receptor (TCR)-based therapeutics.

Key Takeaways:

  • The study highlights the significant immunogenicity of shared neoantigens, including KRAS, TP53, and PIK3CA mutations, across various tumor types.
  • Clinical trials targeting these public neoantigens have yielded encouraging results, including tumor regression and prolonged relapse-free survival.
  • Researchers at Chongqing Medical University have identified four TCR clones specific to the KRASG12V peptide, with one TCR (KT18) exhibiting superior functional avidity and effectively recognizing and eliminating KRASG12V mutant tumor cells without off-target activity.
  • The cross-recognition of the self-antigen RAB7B represents a critical safety consideration when developing HLA-A*11:01-restricted KRASG12V[9]-specific TCRs.
  • The study's findings have significant implications for the development of TCR-based therapeutics against KRASG12V-driven solid tumors.

Statistics:

  • The study reports that clinical trials targeting public neoantigens have yielded encouraging results, resulting in tumor regression and prolonged relapse-free survival in solid tumors.
  • The researchers identified four TCR clones specific to the KRASG12V peptide, with one TCR (KT18) exhibiting superior functional avidity.
  • The study found that HLA-A*11:01-presented KRASG12V epitopes exhibited the strongest HLA binding stability among public neoantigen-HLA pairings.

Sources:

  • Wang, Wang, et al. "Therapeutic potential of T-cell receptor targeting the HLA-A*11:01-restricted KRASG12V neoantigen without cross-recognition of the self-antigen RAB7B in solid tumors." Journal for ImmunoTherapy of Cancer, vol. 13, no. 7, 2025, doi: 10.1136/jitc-2025-011863.
  • Chongqing Medical University. "Therapeutic potential of T-cell receptor targeting the HLA-A*11:01-restricted KRASG12V neoantigen without cross-recognition of the self-antigen RAB7B in solid tumors." Journal for ImmunoTherapy of Cancer, vol. 13, no. 7, 2025.